Lisa Nardelli

1.0k total citations
12 papers, 230 citations indexed

About

Lisa Nardelli is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Lisa Nardelli has authored 12 papers receiving a total of 230 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 4 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Lisa Nardelli's work include Acute Myeloid Leukemia Research (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Lisa Nardelli is often cited by papers focused on Acute Myeloid Leukemia Research (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Lisa Nardelli collaborates with scholars based in United States. Lisa Nardelli's co-authors include Kenneth H. Shain, Xiuhua Zhao, Melissa Alsina, Sundar Jagannath, Rachid Baz, Daniel M. Sullivan, Hui‐Yi Lin, Hearn Jay Cho, Jeffrey L. Wolf and Thomas G. Martin and has published in prestigious journals such as Blood, American Journal of Hematology and Leukemia Research.

In The Last Decade

Lisa Nardelli

11 papers receiving 226 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Nardelli United States 8 183 160 114 30 23 12 230
Despoina Mparmparoussi Greece 6 255 1.4× 232 1.4× 140 1.2× 5 0.2× 33 1.4× 10 272
Rafael Martínez-Martinez Mexico 4 191 1.0× 181 1.1× 118 1.0× 10 0.3× 14 0.6× 6 236
Grzegorz Charliński Poland 8 70 0.4× 56 0.3× 62 0.5× 9 0.3× 21 0.9× 23 132
Christopher Maisel United States 7 89 0.5× 79 0.5× 53 0.5× 5 0.2× 15 0.7× 20 127
José-María Arguiñano Spain 2 125 0.7× 104 0.7× 55 0.5× 4 0.1× 15 0.7× 4 128
Olimpia Finizio Italy 7 149 0.8× 83 0.5× 30 0.3× 22 0.7× 18 0.8× 8 175
J.-Th. Fischer Germany 5 72 0.4× 52 0.3× 28 0.2× 14 0.5× 17 0.7× 9 101
B Chen China 7 185 1.0× 111 0.7× 20 0.2× 13 0.4× 62 2.7× 9 262
Carol Delaney United States 2 122 0.7× 110 0.7× 62 0.5× 5 0.2× 8 0.3× 4 130
Ashraf Elghandour Egypt 5 119 0.7× 133 0.8× 71 0.6× 7 0.2× 6 0.3× 11 174

Countries citing papers authored by Lisa Nardelli

Since Specialization
Citations

This map shows the geographic impact of Lisa Nardelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Nardelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Nardelli more than expected).

Fields of papers citing papers by Lisa Nardelli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Nardelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Nardelli. The network helps show where Lisa Nardelli may publish in the future.

Co-authorship network of co-authors of Lisa Nardelli

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Nardelli. A scholar is included among the top collaborators of Lisa Nardelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Nardelli. Lisa Nardelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Chan, Onyee, Kendra Sweet, Fatima Tuz Zahra, et al.. (2024). Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia. Blood. 144(Supplement 1). 4270–4270.
2.
3.
Sallman, David A., Rami S. Komrokji, Kendra Sweet, et al.. (2019). A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leukemia Research. 81. 56–61. 24 indexed citations
4.
Komrokji, Rami S., Sheng Wei, Adam W. Mailloux, et al.. (2018). A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clinical Lymphoma Myeloma & Leukemia. 19(3). 157–161. 30 indexed citations
5.
Mirza, Abu‐Sayeef, Jeffrey E. Lancet, Kendra Sweet, et al.. (2017). A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 17(12). 902–907. 7 indexed citations
6.
Baz, Rachid, Thomas G. Martin, Hui‐Yi Lin, et al.. (2016). Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 127(21). 2561–2568. 116 indexed citations
7.
8.
Lancet, Jeffrey E., Rami S. Komrokji, Kendra Sweet, et al.. (2016). Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS). Blood. 128(22). 3174–3174. 6 indexed citations
9.
Komrokji, Rami S., Adam W. Mailloux, Ling Zhang, et al.. (2014). A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Blood. 124(21). 4653–4653. 7 indexed citations
10.
11.
Baz, Rachid, Kenneth H. Shain, Mohamad A. Hussein, et al.. (2013). Phase II study of pegylated liposomal doxorubicin, low‐dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. American Journal of Hematology. 89(1). 62–67. 7 indexed citations
12.
Baz, Rachid, Kenneth H. Shain, Melissa Alsina, et al.. (2012). Oral Weekly Cyclophosphamide in Combination with Pomalidomide and Dexamethasone for Relapsed and Refractory Myeloma: Report of the Dose Escalation Cohort. Blood. 120(21). 4062–4062. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Despoina Mparmparoussi Breakdown of academic impact, for papers by Rafael Martínez-Martinez Breakdown of academic impact, for papers by Grzegorz Charliński Breakdown of academic impact, for papers by Christopher Maisel Breakdown of academic impact, for papers by José-María Arguiñano Breakdown of academic impact, for papers by Olimpia Finizio Breakdown of academic impact, for papers by J.-Th. Fischer Breakdown of academic impact, for papers by B Chen Breakdown of academic impact, for papers by Carol Delaney Breakdown of academic impact, for papers by Ashraf Elghandour
Rankless by CCL
2026